Navigation Links
DATATRAK International, Inc. Announces Year-End Backlog
Date:1/13/2010

CLEVELAND, Jan. 13 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today reported its year-end backlog as of December 31, 2009.

At December 31, 2009, backlog was $9,487,000 compared to $8,891,000 at September 30, 2009, a 7% increase. The December 31, 2009 backlog amount of $9,487,000 represents the second consecutive quarter-over-quarter increase in backlog.

"I think our DATATRAK ONE™ vision of a unified technology solution has really taken hold with drug trial sponsors and Contract Research Organizations (CROs) and is evident by the increase in backlog," stated Laurence Birch, Chairman of the Board of DATATRAK International, Inc. "A lot of our competitors market the interoperability of their product offerings, which by definition means the capability of two or more software routines to work harmoniously together. While this might be true, it means extra work, additional cost and ultimately a heightened risk for compromised data. Our clients, unlike our competitors' clients, don't have to worry about interoperability issues such as database reconciliation, stale data vs. real-time data, multiple user names and passwords and undertaking additional validation efforts. Our unified solution has been built entirely on one platform with no required linkage to external systems or scheduled routines."

About DATATRAK International, Inc.

DATATRAK International, Inc. is a worldwide technology and services company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. We operate under the vision of DATATRAK ONE™, which encompasses our unique, single platform technology. The singular architecture of our DATATRAK eClinical™ product suite has been embraced by clients around the globe for its ability to effectively manage clinical trials through a unified multi-component, comprehensive solution. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical™ software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Visit the DATATRAK International, Inc. web site at www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE DATATRAK International, Inc.

RELATED LINKS
http://www.datatrak.net

'/>"/>

SOURCE DATATRAK International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0
2. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
3. DATATRAK International Reports First Quarter Results for 2008
4. European Division of Global Top 20 Pharmaceutical Company Awards Phase III Trial to DATATRAK
5. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
6. DATATRAK eClinical(TM) Supports Multifaceted Studies
7. DATATRAK to Present at 2009 SCDM Annual Conference
8. DATATRAK Signs 6 Year Study with New Device Client
9. DATATRAK Signs Five-Year Registry Study
10. DATATRAKs eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM)
11. PFC Pharma Joins DATATRAKs CRO Connect Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , Jan. 24, 2017 Results show ... dose compared with linac-based radiotherapy platforms Elekta ... spares healthy brain tissue and delivers a higher radiation dose ... patients undergoing radiosurgery for large or complex brain tumors, were ... ...
(Date:1/24/2017)... -- www.Financialbuzz.com - The cannabis market ... the United States as eight more states had ... 64, the California Cannabis Legalization Initiative, was passed by a ... 2016. This outcome means that individuals in California ... certain amount of cannabis for personal use. According to a ...
(Date:1/24/2017)... SAN FRANCISCO , January 24, 2017 ... reach a value of USD 3.8 billion by 2025, ... Inc. The market growth can be attributed to the ... awareness about early diagnosis of micro calcifications in breast ... Cancer Foundation, CDC, and Breast Cancer Organization are promoting ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... 2017 , ... Bellus Medical, a leader in medical aesthetics, today announced that ... role Dr. Dobke will provide physician oversight for in-house clinical studies and hands-on device ... Surgery and Associate Professor of Surgery at UC San Diego Health and is a ...
(Date:1/24/2017)... IA (PRWEB) , ... January 24, 2017 , ... The ... country, has taken great care to design a program that provides teachers with the ... and domestically. This online teaching certificate is ideal for post-baccalaureate students and HigherEducation.com is ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... Ph.D., http://www.faculty.washington.edu/ghp , Sharon Kleyne, the nation’s foremost water advocate and ... Climate Change and Your Health on Voice America, once again welcomed one of ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... a leading natural supplement for relieving premenstrual syndrome, or PMS . , ... some point. These symptoms can include cramps, constipation, irritability, headaches, fatigue, and other ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... to improve the connection with God. “Spiritual Vitamins: A Spiritual Energy Booster” is ... by Christian Faith Publishing, Mathai Yohannan’s new book engages the mind and spirit ...
Breaking Medicine News(10 mins):